FDA Guidance on CT Mgmt during COVID-19
Health Care, Pharma Industry, Strategic Planning
FDA issued this guidance to provide general considerations to assist sponsors in assuring the safety of trial participants, maintaining compliance with good clinical practice (GCP), and minimizing risks to trial integrity during the COVID-19 pandemic.
Related Education Resources.
All ResourcesGCSG 2020 Global Virtual Conference Tour
Topic: Conference
Video
Free
Leadership Lessons for Re-Entry
Topics: Leadership, Management
Webinar
Free
Industry Evolution – A Vision of the Clinical Supply Chain in the Next Decade
Topic: Supply Chain
White Paper
Free
